Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
2.650
-0.020 (-0.75%)
At close: Jun 12, 2025, 4:00 PM
2.620
-0.030 (-1.13%)
Pre-market: Jun 13, 2025, 7:00 AM EDT
Taysha Gene Therapies Employees
Taysha Gene Therapies had 73 employees as of December 31, 2024. The number of employees increased by 21 or 40.38% compared to the previous year.
Employees
73
Change (1Y)
21
Growth (1Y)
40.38%
Revenue / Employee
$98,959
Profits / Employee
-$1,188,575
Market Cap
568.85M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 73 | 21 | 40.38% |
| Dec 31, 2023 | 52 | -13 | -20.00% |
| Dec 31, 2022 | 65 | -113 | -63.48% |
| Dec 31, 2021 | 178 | 140 | 368.42% |
| Dec 31, 2020 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
TSHA News
- 6 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program - GlobeNewsWire
- 14 days ago - Why Is Taysha Gene Therapies Stock Trading Higher On Thursday? - Benzinga
- 15 days ago - Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 15 days ago - Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 15 days ago - Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102 - GlobeNewsWire
- 4 weeks ago - Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire